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epidermal receptor 2-positive advanced gastric
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Abstract
The aim of this study is to report first preliminary results of patients enrolled in a phase II study that will investigate the activity and
safety of docetaxel, oxaliplatin, and 5-fluorouracil (DOF) in combination with trastuzumab in human epidermal receptor-2 (HER-2)
positive patients with advanced gastric or gastroesophageal junction (GEJ) cancer.
Treatment consisted of docetaxel 70mg/m2 combined with oxaliplatin 130mg/m2 on day 1, and continuous infusion 5-fluorouracil
mg/m2 days 1–5 plus trastuzumab at the standard dose on day 1, every 3 weeks for a maximum of 8 cycles.
Fifteen patients were enrolled. The overall response rate was 60%. The median progression-free survival was 9.2 months (95%
confidence interval [CI], 4.4–10.1 months) and the median overall survival was 19.4 months (95% CI, 8.9–21.1 months). Grade 3
neutropenia was observed in 3 patients (20%).
The DOF plus trastuzumab seems active in HER-2 positive advanced gastric or GEJ cancer, final results of the phase II study are
awaited.
Abbreviations: CR = complete response, DCR = disease-control rate, DOF = docetaxel/oxaliplatin/5-FU, EOF = epirubicin/
oxaliplatin/5-fluorouracil, GEJ = gastroesophageal junction, HER2 = human epidermal receptor 2, NCI = National Cancer Institute,
OS = overall survival, PD = progressive disease, PFS = progression free survival, PR = partial response, SD = stable disease.
Keywords: docetaxel, fluorouracil, gastric cancer, human epidermal receptor-2, oxaliplatin, trastuzumab
1. Introduction
Gastric or gastroesophageal junction (GEJ) cancer is considered
one of the most important cause of death related to cancer in
Europe.[1] Surgical resection is the standard for long-term
curative results,[2,3] unfortunately only one-third of patients
are ideal candidates to radical surgery while for patients with
locally advanced or metastatic disease at diagnosis, systemic
chemotherapy with a platinum compound and a fluoropyrimi-
dine is considered the standard of treatment.[4] However, several
studies have proposed a triplet drug combinations with the
addition of taxane or antracycline[5] and recently a metanalysis
has suggested similar activity of docetaxel and epirubicin-based
chemotherapeutic regimens.[5] In this context, we previously
reported that a sequential treatment with a triplet combination of
epirubicin/oxaliplatin/5fluorouracil (EOF) and docetaxel/oxali-
platin/5-FU (DOF) is active against metastatic gastroesophageal
cancer.[6]
Trastuzumab is a humanized recombinant monoclonal anti-
body that selectively binds to the extracellular domain of human
epidermal receptor 2 (HER2).[7] The trastuzumab for gastric
cancer (ToGA) trial evaluated the combination of trastuzumab
with a cisplatin/fluoropyrimidine chemotherapy doublet in
patients with previously untreated advanced HER2-positive
gastroesophageal cancer[8] showing a survival benefit. However,
little data are available on efficacy and toxicity of a triplet taxane-
based regimen chemotherapy for HER2-positive gastroesopha-
geal tumors. Therefore, we investigated the feasibility and
preliminary efficacy of DOF chemotherapy in combination with
trastuzumab as first line in patients with gastroesophageal cancer,
hereby we report the results of first 15 patients with a brief
overview of literature.
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2. Methodology
The complete methodology is reported in supplementary data,
http://links.lww.com/MD/C247, we briefly describe here for
convenience. The study enrolled patients with histologically
proven advanced adenocarcinoma of the stomach or GEJ HER2-
positive tumors who had not previously received chemotherapy
for advanced disease. The other eligibility criteria included age
>18 years, Eastern Cooperative Oncology Group performance
status of 0 to 1, bidimensionally measurable disease, a life
expectancy of at least 6 months, adequate hematological and
biochemical parameters, baseline left ventricular ejection fraction
≥50%. Patients with operable metastatic disease were excluded
from the study, as were those with severe cardiac dysfunction,
chronic diarrhea, or uncontrolled sites of infection. This study
was approved by the local ethical and scientific committee, and all
of the patients gave their written informed consent.
The pretreatment evaluation, performed within 2 weeks before
study entry. During treatment, physical examination and blood
test were mandatory before each course, and left ventricular
ejection fraction was assessed every 3 month. Treatment response
was evaluated every 4 3-weekly cycles or sooner if clinically
indicated. Tumor response was assessed using the RECIST 1.1
criteria.[9]
Treatment consisted of intravenous (i.v.) docetaxel 70mg/m2
combined with 6-hour i.v. l-OHP 130mg/m2 on day 1, and c.i.
5FU 750mg/m2 days 1–5 (DOF regimen) plus trastuzumab
intravenously as a 90-min infusion at doses of 8mg/kg (loading
dose in first cycle) and 6mg/kg (maintenance doses) on day 1,
every 3 weeks. This schedule was repeated until disease
progression, development of unacceptable toxicity, or patient
withdrawal of consent. After the completion of 8 cycles, the
patients who achieved complete or partial response or stable
disease continued the maintenance treatment with c.i. 5FU 750
mg/m2 days 1–5 every 3 weeks and trastuzumab 6mg/kg until
progressive disease or unacceptable toxicity.
Toxicity was assessed using the common toxicity criteria of the
National Cancer Institute (NCI), version 3.0. Treatment was
delayed if, on the planned day of treatment, the neutrophil count
was <1,500/mm3, the platelet count was <100,000/mm3, or the
patient had persistent diarrhea or stomatitis >grade 1. Any
patient who required more than 2 weeks for recovery from
adverse reactions was excluded from the study. In the event of
grade 4 hematologic or any other severe (≥grade 3) organ toxicity
in individual patients, the doses of chemotherapy drugs were
reduced by 25% for subsequent courses.
3. Statistical considerations
The primary end-point was 6-months disease-control rate (DCR).
It was calculated that a total of 43 patients would have to be
recruited. Progression free survival (PFS) was calculated as the
time from the first chemotherapy infusion to disease progression
or death. Secondary end points included: safety and overall
survival (OS), measured from the date of start of treatment to the
date of death. Kaplan–Meier method was used to determine PFS
and OS. Statistical analyses were conducted by STATA IC 2012
software (StataCorp LLC, College Station, TX).
4. Results
From October 2011 to May 2017, a total of 15 patients were
enrolled in the study. Baseline characteristics of the patients are
presented in Table 1. The median age was 62 years (range, 45–
74). All patients had a performance status of 0 or 1, and 66.7%
had multiple metastatic sites.
Primary tumor was gastric in 12 patients and GEJ in 3 patients.
Two patients had received prior chemotherapy.
All patients received at least 1 treatment cycle and were
evaluable for response and toxicity. The median number of cycles
was 9 (range, 1–28).
A documented complete response (CR) was observed in 2
(13.3%) patients and partial response (PR) in 7 patients (46.7%),
with an overall response rate of 60% (95% CI, 32–84%). Four
patients (26.7%) had stable disease (SD), and 2 (13.3%)
progressive disease (PD) (Table 2).
Table 1
Characteristics of patients and response to treatment.
Patient Age Sex ECOG
Tumor
location
Gastric
cancer
type
Primary
tumor
resected
No. of
sites of
disease
Previous
adjuvant
chemotherapy
HER2
status
1 62 M 0 Stomach Mixed Yes 1 No 3+
2 64 M 0 Stomach Intestinal No 3 No 3+
3 68 M 1 Gastroesophageal
junction
Intestinal No 2 No 3+
4 74 F 1 Stomach Intestinal Yes 2 Yes 3+
5 45 M 0 Stomach Intestinal No 1 No 3+
6 60 M 1 Gastroesophageal
junction
Intestinal No 4 No 3+
7 69 F 0 Stomach Diffuse No 3 No 3+
8 53 F 0 Stomach Intestinal No 1 No 3+
9 48 M 0 Stomach Mixed No 6 No 3+
10 63 M 0 Stomach Intestinal Yes 2 No 3+
11 65 F 0 Stomach Intestinal No 2 No 3+
12 38 M 0 Stomach Intestinal No 1 No 2+
13 71 M 1 Gastroesophageal
junction
Diffuse Yes 4 Yes 3+
14 44 F 1 Stomach Mixed No 3 No 2+
15 54 M 0 Stomach Intestinal No 1 No 3+
HER2=human epidermal receptor 2.
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The median PFS of the patients was 9.2 months (95% CI, 4.4–
10.1 months): 9 patients (60%) were progression-free after about
6 months from the onset of chemotherapy (Fig. 1). After the
completion of 8 cycles of DOF, 8 patients started maintenance
therapy. No patient was lost to follow-up. A total of 9 patients
received a further treatment line at documentation of progressive
disease (mainly ramucirumab-based therapy).
At a median follow-up time of 15.9 months, 11 patients were
deceased: the median OS was 19.4 months (95% CI, 8.9–21.1
months) (Fig. 1).
Toxicity during DOF plus trastuzumab was acceptable and
easily manageable with adequate supportive care (Table 1
supplementary data, http://links.lww.com/MD/C247). One pa-
tient interrupted DOF treatment after 3 cycles for toxicity-
unrelated reasons. Three of 15 patients experienced at least 1
episode of grade 3 neutropenia without neutropenic fever.
Among non-hematologic toxicities, grade 4 was not observed:
grade 3 nausea/vomiting, diarrhea, and stomatitis was reported
in 2, 1, and 1 patient, respectively. A total of 11 DOF cycles were
delayed for at least 1 week because of toxicity, and dose
reductions were required in 3 patients.
No patient had an infusion reaction to trastuzumab and no
moderate to severe cardiotoxicity was observed, a cardiac event
consisting of a grade 1 atrial fibrillation was reported in 1 patient.
5. Discussion
The ToGA study demonstrated that trastuzumab in combination
with cisplatin plus capecitabine or fluorouracil was superior to
cisplatin plus capecitabine or fluorouracil alone[8] in term of
tumor response, PFS and OS in patients with HER2-positive
advanced gastric cancer. Based on this data, trastuzumab was
approved in combination with chemotherapy as first line of
treatment in patients with metastatic HER2-overexpressing
gastric or GEJ adenocarcinoma. From this landmark trial, other
studies evaluated the efficacy of different chemotherapeutic
agents in HER-2 positive gastric or EGJ cancer. In 2011, a small
multicenter phase II trial evaluated the activity and safety of
trastuzumab in combination with cisplatin in patients with
advanced non-resectable HER2-positive gastric or GEJ adeno-
carcinoma.[10] Although with the limitation of a small sample
size, cisplatin and trastuzumab achieved a response rate in 32%
of patients with a disease control in 64%. Median time to
progression was 5.1months, while data onOSwere not reported.
Another Japanese phase II study evaluated the efficacy and safety
of S-1 plus cisplatin plus trastuzumab inHER2-positive advanced
gastric cancer.[11] The authors enrolled a total of 54 patients and
the response rate was 68%, and the disease control rate was 94%.
Median OS, PFS, and time to treatment failure were 16.0, 7.8,
and 5.7 months, respectively. Finally, TRIO-013/LOGiC was a
multicenter, double-blind, randomized phase III study that
randomized capecitabine and L-HOP plus lapatinib 1.250mg
or placebo in patients with previously untreated HER2-amplified
advanced gastroesophageal adenocarcinoma.[12] Unfortunately,
the addition of lapatinib to chemotherapy failed to increase
survival. Other studies that investigated trastuzumab in combi-
nation with chemotherapy in HER2-positive advanced gastric
cancer are summarized in Table 3.[13–21]
Albeit with the limitations of a small sample size (only 15
patients from a preliminary analysis), the current study indicates
the feasibility and efficacy of a first-line treatment with a DOF
regimen plus trastuzumab with 9.2 months of median PFS and
19.4 months of median OS. These results compare well with the
best ones reported in this disease for the HER2-positive gastric or
GEJ cancer (Table 3). However, our results must be interpreted
with caution because of we excluded patients with performance
status >1 that were enrolled in the ToGA and LoGic trials
(Table 2 supplementary data, http://links.lww.com/MD/C247).
As known, these patients had a very poor outcome and survival.
In addition, a preplanned exploratory analysis of the ToGA trial
suggested that a strongest expression of HER2 (IHC 3+) is able to
predict the survival of patients treated with trastuzumab with an
improvement in OS of >5 months for patients with IHC 3+
compared with patients with IHC 2+ and fluorescent in situ
hybridization (FISH) positive. In our study, we must report that
only 2 patients had IHC 2+ and subsequent FISH positive as
definition of HER2-positivity. However, the nature of our results
of the current study (preliminary data from a small sample size) is
a limitation which should be considered for a correct their
Figure 1. Kaplan–Mayer curve of progression free survival and overall survival.
Table 2
Best response to treatment of enrolled patients.
Patient
Best response
to treatment by
RECIST criteria
PFS,
(mo)
OS,
(mo) Status
1 PR 9.6 20.4 Dead
2 SD 5.3 16.5 Dead
3 PR 11.8 23 Dead
4 CR 13.1 34.4 Dead
5 PR 10.1 21.1 Dead
6 PR 5.4 9.6 Dead
7 SD 10 19.4 Dead
8 PR 7.7 13.9 Dead
9 PD 1.5 4.5 Dead
10 CR 9.4 9.4 Alive without progression
11 SD 4.4 8.9 Dead
12 PR 5.6 5.6 Alive without progression
13 PD 2.4 4.1 Dead
14 PR 9.2 16.8 Alive
15 SD 6.6 15.9 Alive
CR= complete response, OS= overall survival, PFS=progression free survival, PR=partial response,
SD= stable disease.
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interpretation and thus, caution should be exercised before
drawing firm conclusions.
In order to improve the efficacy of trastuzumab and
chemotherapy in HER2 advanced metastatic gastric cancer,
different approach or combinations have been tested. In 2016, Li
et al[22] reported the results of a phase II study which aims to
analyze the benefit and risk associated with continuing
trastuzumab treatments after first line progression, in addition,
a multicenter, single-arm, phase II study had combined
bevacizumab and trastuzumab with docetaxel, oxaliplatin,
and capecitabine as first-line treatment of advanced HER2-
positive gastric cancer.[23] However, although a certain
efficacy has been observed, these approaches should be validated
in larger randomized phase III studies. Finally, Pertuzumab, a
new humanized anti-HER2 antibody, almost tested in breast
cancer in combination with trastuzumab, has shown to achieve
partial response in the 86% of HER2-positive advanced gastric
cancer when combined with capecitabine and cisplatin chemo-
therapy.[24] Based on these results, the JACOB phase III study (a
study of pertuzumab in combination with trastuzumab and
chemotherapy in patients with HER2-positive metastatic gastric
cancer; NCT01774786) has been conducted and recently
completed. The results of the JACOB study are awaited to
define the role of pertuzumab inHER2-positivemetastatic gastric
cancer.
In summary, the conventional triple drug regimen DOF in
combination with trastuzumab seems a feasible and encouraging
option in HER2-positive advanced gastric or GEJ cancer. The
final results of the phase II study are awaited to confirm these
conclusions.
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